<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981888</url>
  </required_header>
  <id_info>
    <org_study_id>1606244063</org_study_id>
    <nct_id>NCT02981888</nct_id>
  </id_info>
  <brief_title>Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome</brief_title>
  <acronym>IBS</acronym>
  <official_title>Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome and Control Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the relationship between the bile acids, fatty acids&#xD;
      (fatty acids are part of the diet) and bacteria that are present in the intestines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is emerging evidence that alterations in bile acids and SCFA associated with IBS could&#xD;
      be associated with changes in the gut microbiota. In addition to modulating levels of&#xD;
      intraluminal organic acids, it has been hypothesized that gut microbiota may alter local&#xD;
      immune responses, modulate visceral pain responses, and impair gut barrier function.&#xD;
&#xD;
      Our overall goal is to investigate the relationship between fecal bile acids, SCFA and the&#xD;
      gut microbiota in IBS. Results of this pilot study could reveal insights into the interplay&#xD;
      of the gut microbiota and small molecule mediators of IBS to suggest targeted clinical&#xD;
      strategies for improved diagnosis and management of this important syndrome.&#xD;
&#xD;
      AIM 1: Test the hypothesis that fecal organic acids (SFCA and bile acids) and fecal&#xD;
      microbiota play an important role in IBS.&#xD;
&#xD;
      AIM 2: Test the hypothesis that there is association between colonic transit and fecal&#xD;
      microbiota in IBS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total and individual fecal bile acid excretion</measure>
    <time_frame>two days</time_frame>
    <description>Stool samples will be collected over 2 days for measurement of fecal bile acids (µmol/48h) by high performance liquid chromatography-mass spectometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total fecal excretion of short chain fatty acids</measure>
    <time_frame>two days</time_frame>
    <description>Stool samples will be collected for measurement of measurement of short chain fatty acids (µg/mg) by liquid chromatography-mass spectrometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal microbial population and community from stool collection</measure>
    <time_frame>two days</time_frame>
    <description>Stool samples will be be collected from participants for nucleic acid extraction, 16S allele PCR and sequencing to measure microbial communities and profiles of specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal excretion of individual short chain fatty acids</measure>
    <time_frame>two days</time_frame>
    <description>Stool samples will be collected for measurement of measurement of short chain fatty acids (µg/mg) by liquid chromatography-mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool characteristics</measure>
    <time_frame>14 days</time_frame>
    <description>Stool characteristics will be measured using a 14 day bowel diary</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall and segmental colon transit</measure>
    <time_frame>7 days</time_frame>
    <description>Colonic transit time will be measured in days using radiopaque markers</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>IBS</condition>
  <arm_group>
    <arm_group_label>IBS-C</arm_group_label>
    <description>all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBS-D</arm_group_label>
    <description>all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heathy control</arm_group_label>
    <description>all healthy controls will undergo an abdominal x-ray for assessment of colonic transit</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>X-Ray</intervention_name>
    <description>X-ray of the abdomen will be performed to assess colonic transit</description>
    <arm_group_label>IBS-C</arm_group_label>
    <arm_group_label>IBS-D</arm_group_label>
    <arm_group_label>heathy control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target study population will be patients with IBS (both diarrhea- and&#xD;
        constipation-predominant) and healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with IBS, ages 18-65 fulfilling Rome IV criteria and asymptomatic controls&#xD;
             with no prior history of GI disease or symptoms.&#xD;
&#xD;
          -  Participants should be on a stable and consistent diet regimen and should not be&#xD;
             following an extreme diet intervention such as gluten-free or a low FODMAP diet at the&#xD;
             time of study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with microscopic/lymphocytic/collagenous colitis, inflammatory bowel&#xD;
             disease, celiac disease, visceral cancer, chronic infectious disease,&#xD;
             immunodeficiency, uncontrolled thyroid disease, history of liver disease or history of&#xD;
             elevated AST/ALT &gt; 2.0x the upper limit of normal&#xD;
&#xD;
          -  Prior radiation therapy of the abdomen or abdominal surgeries with the exception of&#xD;
             appendectomy or cholecystectomy &gt; 6 months prior to study initiation&#xD;
&#xD;
          -  Ingestion of any prescription, over the counter, or herbal medications which can&#xD;
             affect GI transit or study interpretation (e.g. opioids, narcotics, anticholinergics,&#xD;
             norepinephrine reuptake inhibitors, nonsteroidal anti-inflammatory drugs, COX-2&#xD;
             inhibitors, bile acid sequestrants) within 6 months of study initiation for&#xD;
             asymptomatic volunteers or within 2 days before study initiation for IBS patients&#xD;
&#xD;
          -  Any females who are pregnant or trying to become pregnant or breast-feeding&#xD;
&#xD;
          -  Antibiotic usage within 3 months prior to study participation&#xD;
&#xD;
          -  Prebiotic or probiotic usage within the 2 weeks prior to study initiation&#xD;
&#xD;
          -  Use of tobacco products within the past 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Shin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alka Kadariya</last_name>
    <phone>(317) 278-9296</phone>
    <email>akadariy@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anita Gupta, MBBS,CCRC</last_name>
    <phone>(317) 948-9227</phone>
    <email>anigupta@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Gupta, MBBS, MPH</last_name>
      <phone>317-948-9227</phone>
      <email>anigupta@iu.edu</email>
    </contact>
    <investigator>
      <last_name>John Wo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anita Gupta, MBBS, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Andrea Shin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

